^
Association details:
| Biomarker: | CLDN18 fusion |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | paclitaxel (Bcl2 inhibitor, Tubulin polymerization promoter) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
157P - CLDN18 fusions rather than expression is a biomarker related to the efficacy of paclitaxel in patients with ovarian metastasis of gastric cancer
Published date:
10/16/2023
Excerpt:
IHC was performed on six CLDN18 fusion patients and twelve patients with different responses to paclitaxel….We have identified potential biomarkers, including CLDN18, that could predict the efficacy of paclitaxel treatment based on the differential response to treatment. We have also confirmed that CLDN18 fusion is a potential predictive biomarker for paclitaxel treatment response...
